Summary of Study ST002317
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001485. The data can be accessed directly via it's Project DOI: 10.21228/M8S41S This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002317 |
| Study Title | Mass spectroscopy‑based proteomics and metabolomics analysis of triple‑positive breast cancer cells treated with tamoxifen |
| Study Summary | HER2-enriched breast cancer with high levels of hormone receptor expression, known as triple positive breast cancer, may represent a new entity with a relatively favourable prognosis against which the combination of chemotherapy, HER-2 inhibition, and endocrine treatment may be considered overtreatment. We explored the effect of the anticancer drugs tamoxifen and trastuzumab, both separately and in combination, on the integrated proteomic and metabolic profile of triple positive breast cancer cells (BT-474). Method We employed ultra-high-performance liquid chromatography-quadrupole time of flight mass spectrometry using a Bruker timsTOF to investigate changes in BT-474 cell line treated with either tamoxifen, trastuzumab or a combination. Differentially abundant metabolites were identified using the Bruker Human Metabolome Database metabolite library and proteins using the Uniprot proteome for Homo sapiens using MetaboScape and MaxQuant, respectively, for identification and quantitation. Results A total of 77 proteins and 85 metabolites were found to significantly differ in abundance in BT-474 treated cells with tamoxifen 5 μM/and or trastuzumab 2.5 μM. Findings suggest that by targeting important cellular signalling pathways which regulate cell growth, apoptosis, proliferation, and chemoresistance, these medicines have a considerable anti-growth effect in BT-474 cells. Pathways enriched for dysregulation include RNA splicing, neutrophil degranulation and activation, cellular redox homeostasis, mitochondrial transmembrane transport, ferroptosis and necroptosis, ABC transporters and central carbon metabolism. Conclusion Our findings in protein and metabolite level research revealed that anti-cancer drug therapy had a significant impact on the key signalling pathways and molecular processes in triple positive BT-474 cell lines. |
| Institute | University of Sharjah |
| Department | Sharjah Institute for Medical Research |
| Laboratory | Biomarker Discovery Group |
| Last Name | Soares |
| First Name | Nelson |
| Address | M32, SIMR, College of Pharmacy, Health Sciences, University of Sharjah |
| nsoares@sharjah.ac.ae | |
| Phone | 065057656 |
| Submit Date | 2022-10-18 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | d |
| Analysis Type Detail | LC-MS |
| Release Date | 2022-11-21 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Combined analysis:
| Analysis ID | AN003784 |
|---|---|
| Analysis type | MS |
| Chromatography type | Reversed phase |
| Chromatography system | Bruker Elute HPG 1300 |
| Column | Hamilton Intensity Solo 2 C18 |
| MS Type | ESI |
| MS instrument type | QTOF |
| MS instrument name | Bruker timsTOF |
| Ion Mode | POSITIVE |
| Units | AU |
Chromatography:
| Chromatography ID: | CH002798 |
| Chromatography Summary: | Samples were chromatographically separated by inline reversed-phase chromatography using the Elute HPG 1300 pumps and Elute Autosampler (Bruker, Darmstadt, Germany) with solvent A 0.1% FA in HPLC grade water and solvent B 0.1% FA in ACN. A Hamilton Intensity Solo 2 C18 column (100 mm × 2.1 mm, 1.8 μm beads) was maintained at 35 ℃ (metabolomics analyses). |
| Methods ID: | . |
| Methods Filename: | . |
| Chromatography Comments: | . |
| Instrument Name: | Bruker Elute HPG 1300 |
| Column Name: | Hamilton Intensity Solo 2 C18 |
| Column Pressure: | . |
| Column Temperature: | 35 |
| Flow Gradient: | 1%B to 99%B in 15 min |
| Flow Rate: | 250 uL/min |
| Injection Temperature: | . |
| Internal Standard: | . |
| Internal Standard Mt: | . |
| Retention Index: | . |
| Retention Time: | . |
| Sample Injection: | . |
| Sampling Cone: | . |
| Solvent A: | 100% water; 0.1% formic acid |
| Solvent B: | 100% acetonitrile; 0.1% formic acid |
| Analytical Time: | . |
| Capillary Voltage: | . |
| Migration Time: | . |
| Oven Temperature: | 35C |
| Preconditioning: | . |
| Running Buffer: | . |
| Running Voltage: | . |
| Sheath Liquid: | . |
| Time Program: | . |
| Transferline Temperature: | . |
| Washing Buffer: | . |
| Weak Wash Solvent Name: | . |
| Weak Wash Volume: | . |
| Strong Wash Solvent Name: | . |
| Strong Wash Volume: | . |
| Target Sample Temperature: | . |
| Sample Loop Size: | . |
| Sample Syringe Size: | . |
| Randomization Order: | . |
| Chromatography Type: | Reversed phase |
